メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
富山大学 ホーム
日本語
English
ホーム
プロファイル
研究部門
プロジェクト
研究成果
データセット
受賞
活動
コース
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
梶浦 新也
講師, 学士（医学） 富山医科薬科大学 1999年3月
臨床腫瘍学講座
h-index
562
被引用数
13
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2003
2025
年別の研究成果
概要
フィンガープリント
ネットワーク
プロジェクト
(1)
研究成果
(71)
データセット
(20)
コース
(14)
類似のプロファイル
(6)
フィンガープリント
Shinya Kajiuraが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Keyphrases
Advanced Gastric Cancer
93%
Cisplatin
54%
Irinotecan
53%
Chemotherapy
42%
Fluoropyrimidine
40%
Gastrointestinal Stromal Tumor
38%
Median Progression-free Survival
34%
5-fluorouracil (5-FU)
33%
Overall Survival
33%
Docetaxel
31%
Combination Chemotherapy
26%
Shakuyakukanzoto
26%
Endoscopic Ultrasound-guided Fine-needle Aspiration (EUS-FNA)
25%
Median Overall Survival
24%
Gastric Cancer
24%
Clinical Outcomes
24%
Metastatic Colorectal Cancer (mCRC)
24%
Monotherapy
24%
Nivolumab
24%
Endoscopic Submucosal Dissection
24%
Oxaliplatin
22%
S-1 Plus Cisplatin
21%
Multicenter Retrospective Study
20%
Preventive Effect
20%
Older Men
19%
Second-line Chemotherapy
19%
Mitomycin C
19%
Intra-aortic Balloon Occlusion
19%
Endoscopic Hemostasis
19%
Endoscopic Retrograde Cholangiopancreatography
19%
Stomach
19%
Franseen Needle
19%
Ulcer
19%
Confidence Interval
19%
Response Rate
19%
Progression-free Survival
19%
First-line Chemotherapy
19%
Clinical Trials
16%
Diarrhea
16%
Gastrointestinal Cancer
16%
Japanese Patients
16%
Phase II Study
15%
Home Death
15%
Resectable Pancreatic Cancer
15%
Ramucirumab
15%
Helicobacter Pylori (H. pylori)
14%
Traditional Japanese Medicine
14%
Neurotoxicity
14%
Liver Metastasis
14%
Colorectal Cancer
14%
Pharmacology, Toxicology and Pharmaceutical Science
Abdominal Cancer
100%
Chemotherapy
92%
Overall Survival
60%
Progression Free Survival
55%
Irinotecan
54%
Cisplatin
54%
Fluoropyrimidine
40%
Adverse Event
34%
Retrospective Study
34%
Fluorouracil
30%
Docetaxel
30%
Oxaliplatin
27%
Monotherapy
26%
Paclitaxel
24%
Metastatic Colorectal Cancer
24%
Combination Therapy
21%
Pancreas Cancer
21%
Mitomycin
19%
Gastrointestinal Stromal Tumor
19%
Neuroendocrine Carcinoma
19%
Imatinib
19%
Clinical Trial
19%
Neoplasm
17%
First-Line Chemotherapy
17%
Nivolumab
17%
Second-Line Chemotherapy
16%
Cetuximab
16%
Diarrhea
16%
Folinic Acid
15%
Ramucirumab
15%
Neurotoxicity
14%
Acute Pancreatitis
12%
Bevacizumab
11%
Colorectal Carcinoma
11%
Inflammatory Bowel Disease
11%
Amrubicin
11%
Pancreatitis
11%
Gemcitabine
11%
Immune Checkpoint Inhibitor
10%
Pembrolizumab
10%
Disease
10%
Crohn's Disease
9%
Liver Cell Carcinoma
9%
Liver Metastasis
9%
Injury
9%
CagA Protein
9%
Immunoglobulin A
9%
Stag
9%
Epidermal Growth Factor Receptor
9%
Infliximab
9%
Medicine and Dentistry
Abdominal Cancer
56%
Overall Survival
28%
Neoplasm
28%
Arm
28%
Chemotherapy
28%
Pancreas Cancer
27%
Endoscopic Ultrasound Guided Fine Needle Biopsy
27%
Nivolumab
24%
Endoscopic Submucosal Dissection
24%
Ulcer
23%
Progression Free Survival
23%
Endoscopic Ultrasound
19%
Fine-Needle Aspiration
19%
Endoscopic Retrograde Cholangiopancreatography
19%
Balloon Occlusion
19%
Endoscopic Hemostasis
19%
Diagnosis
19%
Computer Assisted Tomography
19%
Malignant Neoplasm
17%
Bleeding
16%
Helicobacter Pylori
15%
Gemcitabine
15%
Irinotecan
15%
Endoscopy
14%
Liver Metastasis
14%
Retrospective Study
14%
Cancer
13%
First-Line Chemotherapy
13%
Duodenum
12%
Combination Chemotherapy
12%
Radiofrequency Ablation
12%
Blood Pressure
12%
Clinical Trial
11%
Immunity
11%
Biopsy Technique
11%
Nonsteroid Antiinflammatory Agent
10%
Immune-Related Adverse Events
10%
Metastatic Carcinoma
10%
Hepatocellular Carcinoma
9%
Endoscopic Papillotomy
9%
Esophagus Tumor
9%
N [bis(1 Aziridinyl)phosphinyl] 4 Iodobenzamide
9%
Gastrointestinal Stromal Tumor
9%
Fluoropyrimidine
9%
Duodenum Motility
9%
CagA Protein
9%
Jejunum
9%
Low Drug Dose
9%
Mitomycin
9%
Duodenal Ulcer Bleeding
9%
